C84.7
Non-Billable

Is C84.7 Billable?

No — This is a non-billable / non-specific code. Use a more specific sub-code for billing and reimbursement.

Anaplastic large cell lymphoma, ALK-negative

Billable Alternatives 12 found
C84.70
Anaplastic large cell lymphoma, ALK-negative, unspecified site
Billable
C84.71
Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck
Billable
C84.72
Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes
Billable
C84.73
Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes
Billable
C84.74
Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb
Billable
C84.75
Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb
Billable
C84.76
Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes
Billable
C84.77
Anaplastic large cell lymphoma, ALK-negative, spleen
Billable
C84.78
Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites
Billable
C84.79
Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites
Billable
C84.7A
Anaplastic large cell lymphoma, ALK-negative, breast
Billable
C84.7B
Anaplastic large cell lymphoma, ALK-negative, in remission
Billable

Understanding Billable vs Non-Billable Codes

ICD-10-CM codes are classified as either billable/specific or non-billable/non-specific. Billable codes can be used on insurance claims for reimbursement. Non-billable codes are typically parent or header codes that require a more specific sub-code for actual billing.

When a code is non-billable, always look for its child codes (sub-codes) which provide the necessary specificity for reimbursement. Using a non-billable code on a claim may result in denial or delayed payment.

About Billable Status

Billable status indicates whether a code can be used for reimbursement purposes. Non-billable codes are typically header or parent codes that require a more specific sub-code for actual billing and claims. Always verify with the latest payer guidelines.